Literature DB >> 979066

The effect of saralasin (1sar-8-ala-angiotensin II) on blood pressure in patients with Cushing's syndrome.

W Vetter, H Vetter, R Beckerhoff, B Redlich, P Cottier, W Siegenthaler.   

Abstract

To investigate the role of the renin angiotensin system in the pathogenesis of hypertension in Cushing's syndrome two patients with hypercorticism were infused with 20 mg saralasin (1-sar-8-ala-angiotensin II) over a period of 30 minutes under constant blood pressue control. In addition, one patient with primary aldosteronism, an established form of mineralocorticoid hypertension, served as control. Neither in the two patients with Cushing's syndrome nor in the patient with primary aldosteronism could a blood pressure lowering effect of saralasin be observed. In the two patients with hypercoritcism both renin activity and plasma aldosterone increased during saralasin infusion. The patient with primary aldosteronism only showed a weak increase in plasma aldosterone concentration.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 979066     DOI: 10.1007/BF01469145

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  9 in total

1.  Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients.

Authors:  W A Pettinger; K Keeton; K Tanaka
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

2.  Work of digital vasoconstriction produced by infused norepinephrine in Cushing's syndrome.

Authors:  M MENDLOWITZ; S GITLOW; N NAFTCHI
Journal:  J Appl Physiol       Date:  1958-09       Impact factor: 3.531

3.  Pathogenesis of hypertension in Cushing's syndrome.

Authors:  L Krakoff; G Nicolis; B Amsel
Journal:  Am J Med       Date:  1975-02       Impact factor: 4.965

4.  Plasma renin and the antihypertensive effect of 1-Sar-8-Ala-angiotensin II.

Authors:  D T Pals; F D Masucci
Journal:  Eur J Pharmacol       Date:  1973-07       Impact factor: 4.432

5.  Measurement of plasma renin substrate by radioimmunoassay of angiotensin. I. Concentration in syndromes associated with steroid excess.

Authors:  L R Krakoff
Journal:  J Clin Endocrinol Metab       Date:  1973-07       Impact factor: 5.958

6.  Mechanism of the antihypertensive effect of 1-Sar-8-Ala-angiotensin II during the acute phase of experimental renal hypertension.

Authors:  D T Pals; R W Fulton
Journal:  Arch Int Pharmacodyn Ther       Date:  1973-07

7.  Role of the pressor action of angiotensin II in experimental hypertension.

Authors:  D T Pals; F D Masucci; G S Denning; F Sipos; D C Fessler
Journal:  Circ Res       Date:  1971-12       Impact factor: 17.367

8.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

9.  Radioimmunoassay for aldosterone without chromatography. 2. Determination of plasma aldosterone.

Authors:  W Vetter; H Vetter; W Siegenthaler
Journal:  Acta Endocrinol (Copenh)       Date:  1973-11
  9 in total
  3 in total

1.  [Critical analysis of the saralasintest in the diagnosis of hypertension (author's transl)].

Authors:  A Röckel; H Wernze; B Sabel; A Heidland
Journal:  Klin Wochenschr       Date:  1977-07-01

2.  Captopril in Cushing's syndrome.

Authors:  P Greminger; W Vetter; H Groth; T Lüscher; W Tenschert; W Siegenthaler; H Vetter
Journal:  Klin Wochenschr       Date:  1984-09-17

Review 3.  Cardiovascular consequences of cortisol excess.

Authors:  Judith A Whitworth; Paula M Williamson; George Mangos; John J Kelly
Journal:  Vasc Health Risk Manag       Date:  2005
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.